Last reviewed · How we verify

Sitagliptin combined with metformin

Sun Yat-sen University · FDA-approved active Small molecule

Sitagliptin combined with metformin is a DPP-4 inhibitor combined with biguanide Small molecule drug developed by Sun Yat-sen University. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: Januvia®, Merck & Co. Inc..

Sitagliptin inhibits DPP-4 to increase incretin levels and insulin secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.

Sitagliptin inhibits DPP-4 to increase incretin levels and insulin secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.

At a glance

Generic nameSitagliptin combined with metformin
Also known asJanuvia®, Merck & Co. Inc.
SponsorSun Yat-sen University
Drug classDPP-4 inhibitor combined with biguanide
TargetDPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and reducing glucagon levels. Metformin is a biguanide that decreases hepatic glucose production and increases peripheral glucose uptake and insulin sensitivity. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sitagliptin combined with metformin

What is Sitagliptin combined with metformin?

Sitagliptin combined with metformin is a DPP-4 inhibitor combined with biguanide drug developed by Sun Yat-sen University, indicated for Type 2 diabetes mellitus.

How does Sitagliptin combined with metformin work?

Sitagliptin inhibits DPP-4 to increase incretin levels and insulin secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.

What is Sitagliptin combined with metformin used for?

Sitagliptin combined with metformin is indicated for Type 2 diabetes mellitus.

Who makes Sitagliptin combined with metformin?

Sitagliptin combined with metformin is developed and marketed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).

Is Sitagliptin combined with metformin also known as anything else?

Sitagliptin combined with metformin is also known as Januvia®, Merck & Co. Inc..

What drug class is Sitagliptin combined with metformin in?

Sitagliptin combined with metformin belongs to the DPP-4 inhibitor combined with biguanide class. See all DPP-4 inhibitor combined with biguanide drugs at /class/dpp-4-inhibitor-combined-with-biguanide.

What development phase is Sitagliptin combined with metformin in?

Sitagliptin combined with metformin is FDA-approved (marketed).

What are the side effects of Sitagliptin combined with metformin?

Common side effects of Sitagliptin combined with metformin include Hypoglycemia, Gastrointestinal disturbances (nausea, diarrhea, abdominal pain), Headache, Nasopharyngitis, Lactic acidosis (rare, metformin-related).

What does Sitagliptin combined with metformin target?

Sitagliptin combined with metformin targets DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and is a DPP-4 inhibitor combined with biguanide.

Related